Montelukast and the risk of major adverse cardiovascular events textendash a Danish population-based case-control study

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Resumé

Background: The leukotriene pathway has previously been associated with an increased risk of major adverse cardiologic events (MACE), and emerging evidence suggest that montelukast, a leukotriene receptor antagonist, might be associated with a decreased risk of MACE. The aim was to assess the potential association between montelukast use and the risk of MACE.Methods: We conducted a population-based case-control study based on Danish health register data. We included all adults who at some point during 2000-2016 lived on the island of Funen, and who (pop 490,000 in 2016) had a first-time occurrence of MACE (n=79,622). For each case, we age- and sex-matched up to 10 disease-free controls (n=793,549). Using conditional logistic regression, we estimated odds ratios (ORs) for MACE associated with cumulative use of montelukast.Results: In total, 900 cases (1.1 and 5,764 controls (0.7 had ever use of montelukast within the study period. A total of 20,727 (26 of the cases, and 61,657 (7.8 of the controls had a high burden of comorbidity (Charlson Comorbidity Index >=3). Ever use of montelukast was associated with a decreased risk of MACE when adjusting for comorbidity and education level (adjusted [adj]OR 0.79; 95% confidence interval [CI] 0.73-0.85), but no dose-response patterns were observed (cumulative use >=2000 defined daily doses: adjOR 0.65; 95%CI 0.47-0.88; long-term use >=10 years: adjOR 0.44; 95%CI 0.15-1.25). When further adjusting for respiratory- and antihypertensive treatment the decreased risk of MACE remained almost unchanged (adjOR 0.86; 95%CI 0.79-0.93]).Conclusion: We confirmed the previous reported decreased risk of MACE in patients treated with montelukast.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA4475.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
OriginalsprogEngelsk
ArtikelnummerPA4475
TidsskriftEuropean Respiratory Journal
Vol/bind52
Udgave nummerSuppl. 62
Antal sider1
ISSN0903-1936
DOI
StatusUdgivet - 2018
BegivenhedERS International Congress 2018 - Paris, Frankrig
Varighed: 15. sep. 201819. sep. 2018

Konference

KonferenceERS International Congress 2018
LandFrankrig
ByParis
Periode15/09/201819/09/2018

Fingeraftryk

montelukast
Case-Control Studies
Confidence Intervals
Population
Comorbidity
Odds Ratio
Leukotriene Antagonists
Education
Islands
Logistic Models

Citer dette

@article{270396b04e9145e5b2473b2e0ab17d87,
title = "Montelukast and the risk of major adverse cardiovascular events textendash a Danish population-based case-control study",
abstract = "Background: The leukotriene pathway has previously been associated with an increased risk of major adverse cardiologic events (MACE), and emerging evidence suggest that montelukast, a leukotriene receptor antagonist, might be associated with a decreased risk of MACE. The aim was to assess the potential association between montelukast use and the risk of MACE.Methods: We conducted a population-based case-control study based on Danish health register data. We included all adults who at some point during 2000-2016 lived on the island of Funen, and who (pop 490,000 in 2016) had a first-time occurrence of MACE (n=79,622). For each case, we age- and sex-matched up to 10 disease-free controls (n=793,549). Using conditional logistic regression, we estimated odds ratios (ORs) for MACE associated with cumulative use of montelukast.Results: In total, 900 cases (1.1 and 5,764 controls (0.7 had ever use of montelukast within the study period. A total of 20,727 (26 of the cases, and 61,657 (7.8 of the controls had a high burden of comorbidity (Charlson Comorbidity Index >=3). Ever use of montelukast was associated with a decreased risk of MACE when adjusting for comorbidity and education level (adjusted [adj]OR 0.79; 95{\%} confidence interval [CI] 0.73-0.85), but no dose-response patterns were observed (cumulative use >=2000 defined daily doses: adjOR 0.65; 95{\%}CI 0.47-0.88; long-term use >=10 years: adjOR 0.44; 95{\%}CI 0.15-1.25). When further adjusting for respiratory- and antihypertensive treatment the decreased risk of MACE remained almost unchanged (adjOR 0.86; 95{\%}CI 0.79-0.93]).Conclusion: We confirmed the previous reported decreased risk of MACE in patients treated with montelukast.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA4475.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).",
author = "Henriksen, {Daniel Pilsgaard} and Davidsen, {Jesper R{\o}mhild} and Laursen, {Christian B.}",
year = "2018",
doi = "10.1183/13993003.congress-2018.PA4475",
language = "English",
volume = "52",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "Suppl. 62",

}

TY - ABST

T1 - Montelukast and the risk of major adverse cardiovascular events textendash a Danish population-based case-control study

AU - Henriksen, Daniel Pilsgaard

AU - Davidsen, Jesper Rømhild

AU - Laursen, Christian B.

PY - 2018

Y1 - 2018

N2 - Background: The leukotriene pathway has previously been associated with an increased risk of major adverse cardiologic events (MACE), and emerging evidence suggest that montelukast, a leukotriene receptor antagonist, might be associated with a decreased risk of MACE. The aim was to assess the potential association between montelukast use and the risk of MACE.Methods: We conducted a population-based case-control study based on Danish health register data. We included all adults who at some point during 2000-2016 lived on the island of Funen, and who (pop 490,000 in 2016) had a first-time occurrence of MACE (n=79,622). For each case, we age- and sex-matched up to 10 disease-free controls (n=793,549). Using conditional logistic regression, we estimated odds ratios (ORs) for MACE associated with cumulative use of montelukast.Results: In total, 900 cases (1.1 and 5,764 controls (0.7 had ever use of montelukast within the study period. A total of 20,727 (26 of the cases, and 61,657 (7.8 of the controls had a high burden of comorbidity (Charlson Comorbidity Index >=3). Ever use of montelukast was associated with a decreased risk of MACE when adjusting for comorbidity and education level (adjusted [adj]OR 0.79; 95% confidence interval [CI] 0.73-0.85), but no dose-response patterns were observed (cumulative use >=2000 defined daily doses: adjOR 0.65; 95%CI 0.47-0.88; long-term use >=10 years: adjOR 0.44; 95%CI 0.15-1.25). When further adjusting for respiratory- and antihypertensive treatment the decreased risk of MACE remained almost unchanged (adjOR 0.86; 95%CI 0.79-0.93]).Conclusion: We confirmed the previous reported decreased risk of MACE in patients treated with montelukast.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA4475.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

AB - Background: The leukotriene pathway has previously been associated with an increased risk of major adverse cardiologic events (MACE), and emerging evidence suggest that montelukast, a leukotriene receptor antagonist, might be associated with a decreased risk of MACE. The aim was to assess the potential association between montelukast use and the risk of MACE.Methods: We conducted a population-based case-control study based on Danish health register data. We included all adults who at some point during 2000-2016 lived on the island of Funen, and who (pop 490,000 in 2016) had a first-time occurrence of MACE (n=79,622). For each case, we age- and sex-matched up to 10 disease-free controls (n=793,549). Using conditional logistic regression, we estimated odds ratios (ORs) for MACE associated with cumulative use of montelukast.Results: In total, 900 cases (1.1 and 5,764 controls (0.7 had ever use of montelukast within the study period. A total of 20,727 (26 of the cases, and 61,657 (7.8 of the controls had a high burden of comorbidity (Charlson Comorbidity Index >=3). Ever use of montelukast was associated with a decreased risk of MACE when adjusting for comorbidity and education level (adjusted [adj]OR 0.79; 95% confidence interval [CI] 0.73-0.85), but no dose-response patterns were observed (cumulative use >=2000 defined daily doses: adjOR 0.65; 95%CI 0.47-0.88; long-term use >=10 years: adjOR 0.44; 95%CI 0.15-1.25). When further adjusting for respiratory- and antihypertensive treatment the decreased risk of MACE remained almost unchanged (adjOR 0.86; 95%CI 0.79-0.93]).Conclusion: We confirmed the previous reported decreased risk of MACE in patients treated with montelukast.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA4475.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

U2 - 10.1183/13993003.congress-2018.PA4475

DO - 10.1183/13993003.congress-2018.PA4475

M3 - Conference abstract in journal

VL - 52

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - Suppl. 62

M1 - PA4475

ER -